Does the media favor SRPT or FDMT?

In the previous week, 4D Molecular Therapeutics had 1 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 4 mentions for 4D Molecular Therapeutics and 3 mentions for Sarepta Therapeutics. Sarepta Therapeutics' average media sentiment score of 0.82 beat 4D Molecular Therapeutics' score of 0.54 indicating that Sarepta Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 4D Molecular Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VCEL or FDMT?

In the previous week, 4D Molecular Therapeutics had 2 more articles in the media than Vericel. MarketBeat recorded 4 mentions for 4D Molecular Therapeutics and 2 mentions for Vericel. Vericel's average media sentiment score of 0.93 beat 4D Molecular Therapeutics' score of 0.54 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 4D Molecular Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SNDX or FDMT?

In the previous week, Syndax Pharmaceuticals had 2 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 6 mentions for Syndax Pharmaceuticals and 4 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.54 beat Syndax Pharmaceuticals' score of 0.12 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral 4D Molecular Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NTLA or FDMT?

In the previous week, 4D Molecular Therapeutics had 1 more articles in the media than Intellia Therapeutics. MarketBeat recorded 4 mentions for 4D Molecular Therapeutics and 3 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.10 beat 4D Molecular Therapeutics' score of 0.54 indicating that Intellia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 4D Molecular Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

4D Molecular Therapeutics (FDMT) Competitors

$9.53 +0.26 (+2.80%)

Closing price 04:00 PM Eastern

Extended Trading

$9.28 -0.25 (-2.67%)

As of 05:05 PM Eastern

Compare

FDMT vs. SRPT, VCEL, SNDX, NTLA, and HRMY

Should you buy 4D Molecular Therapeutics stock or one of its competitors? MarketBeat compares 4D Molecular Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with 4D Molecular Therapeutics include Sarepta Therapeutics (SRPT), Vericel (VCEL), Syndax Pharmaceuticals (SNDX), Intellia Therapeutics (NTLA), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry.

How does 4D Molecular Therapeutics compare to Sarepta Therapeutics?

Sarepta Therapeutics (NASDAQ:SRPT) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

Sarepta Therapeutics has a net margin of -2.94% compared to 4D Molecular Therapeutics' net margin of -182.34%. Sarepta Therapeutics' return on equity of 7.56% beat 4D Molecular Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-2.94%	7.56%	2.94%
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%

Sarepta Therapeutics presently has a consensus price target of $27.17, suggesting a potential upside of 67.33%. 4D Molecular Therapeutics has a consensus price target of $29.88, suggesting a potential upside of 213.48%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6 Sell rating(s)	13 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.11
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 6.9% of Sarepta Therapeutics shares are owned by company insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Sarepta Therapeutics has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.75, suggesting that its share price is 175% more volatile than the broader market.

4D Molecular Therapeutics has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.18B	0.78	-$713.41M	-$0.96	N/A
4D Molecular Therapeutics	$85.21M	5.85	-$140.11M	-$2.57	N/A

In the previous week, 4D Molecular Therapeutics had 1 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 4 mentions for 4D Molecular Therapeutics and 3 mentions for Sarepta Therapeutics. Sarepta Therapeutics' average media sentiment score of 0.82 beat 4D Molecular Therapeutics' score of 0.54 indicating that Sarepta Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
4D Molecular Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

4D Molecular Therapeutics beats Sarepta Therapeutics on 9 of the 16 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to Vericel?

Vericel (NASDAQ:VCEL) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

Vericel currently has a consensus price target of $55.40, suggesting a potential upside of 59.47%. 4D Molecular Therapeutics has a consensus price target of $29.88, suggesting a potential upside of 213.48%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe 4D Molecular Therapeutics is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, 4D Molecular Therapeutics had 2 more articles in the media than Vericel. MarketBeat recorded 4 mentions for 4D Molecular Therapeutics and 2 mentions for Vericel. Vericel's average media sentiment score of 0.93 beat 4D Molecular Therapeutics' score of 0.54 indicating that Vericel is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
4D Molecular Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vericel has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.75, suggesting that its stock price is 175% more volatile than the broader market.

Vericel has higher revenue and earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$292.09M	6.07	$16.52M	$0.42	82.71
4D Molecular Therapeutics	$85.21M	5.85	-$140.11M	-$2.57	N/A

Vericel has a net margin of 7.35% compared to 4D Molecular Therapeutics' net margin of -182.34%. Vericel's return on equity of 6.41% beat 4D Molecular Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.35%	6.41%	4.61%
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 7.6% of Vericel shares are held by company insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Vericel beats 4D Molecular Therapeutics on 9 of the 16 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to Syndax Pharmaceuticals?

Syndax Pharmaceuticals (NASDAQ:SNDX) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

4D Molecular Therapeutics has lower revenue, but higher earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	9.43	-$285.42M	-$2.79	N/A
4D Molecular Therapeutics	$85.21M	5.85	-$140.11M	-$2.57	N/A

In the previous week, Syndax Pharmaceuticals had 2 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 6 mentions for Syndax Pharmaceuticals and 4 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.54 beat Syndax Pharmaceuticals' score of 0.12 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
4D Molecular Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 4.1% of Syndax Pharmaceuticals shares are held by company insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Syndax Pharmaceuticals has a net margin of -111.88% compared to 4D Molecular Therapeutics' net margin of -182.34%. 4D Molecular Therapeutics' return on equity of -36.83% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%

Syndax Pharmaceuticals presently has a consensus target price of $42.55, suggesting a potential upside of 131.98%. 4D Molecular Therapeutics has a consensus target price of $29.88, suggesting a potential upside of 213.48%. Given 4D Molecular Therapeutics' higher possible upside, analysts clearly believe 4D Molecular Therapeutics is more favorable than Syndax Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Syndax Pharmaceuticals has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.75, indicating that its stock price is 175% more volatile than the broader market.

Summary

4D Molecular Therapeutics beats Syndax Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to Intellia Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

4D Molecular Therapeutics has a net margin of -182.34% compared to Intellia Therapeutics' net margin of -597.04%. 4D Molecular Therapeutics' return on equity of -36.83% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-597.04%	-57.47%	-46.24%
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%

4D Molecular Therapeutics has higher revenue and earnings than Intellia Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	26.88	-$412.69M	-$3.54	N/A
4D Molecular Therapeutics	$85.21M	5.85	-$140.11M	-$2.57	N/A

In the previous week, 4D Molecular Therapeutics had 1 more articles in the media than Intellia Therapeutics. MarketBeat recorded 4 mentions for 4D Molecular Therapeutics and 3 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.10 beat 4D Molecular Therapeutics' score of 0.54 indicating that Intellia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
4D Molecular Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 3.1% of Intellia Therapeutics shares are held by company insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Intellia Therapeutics has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.75, indicating that its share price is 175% more volatile than the broader market.

Intellia Therapeutics presently has a consensus price target of $20.25, indicating a potential upside of 55.53%. 4D Molecular Therapeutics has a consensus price target of $29.88, indicating a potential upside of 213.48%. Given 4D Molecular Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe 4D Molecular Therapeutics is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

4D Molecular Therapeutics beats Intellia Therapeutics on 12 of the 17 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to Harmony Biosciences?

4D Molecular Therapeutics (NASDAQ:FDMT) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

4D Molecular Therapeutics has a beta of 2.75, indicating that its share price is 175% more volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market.

4D Molecular Therapeutics presently has a consensus target price of $29.88, indicating a potential upside of 213.48%. Harmony Biosciences has a consensus target price of $40.89, indicating a potential upside of 27.51%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe 4D Molecular Therapeutics is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Harmony Biosciences	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27

Harmony Biosciences has higher revenue and earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	5.85	-$140.11M	-$2.57	N/A
Harmony Biosciences	$868.45M	2.14	$158.69M	$2.48	12.93

Harmony Biosciences has a net margin of 16.20% compared to 4D Molecular Therapeutics' net margin of -182.34%. Harmony Biosciences' return on equity of 17.19% beat 4D Molecular Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%
Harmony Biosciences	16.20%	17.19%	11.99%

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are held by institutional investors. 7.9% of 4D Molecular Therapeutics shares are held by company insiders. Comparatively, 11.0% of Harmony Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, 4D Molecular Therapeutics had 3 more articles in the media than Harmony Biosciences. MarketBeat recorded 4 mentions for 4D Molecular Therapeutics and 1 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.34 beat 4D Molecular Therapeutics' score of 0.54 indicating that Harmony Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
4D Molecular Therapeutics	Positive
Harmony Biosciences	Positive

Summary

Harmony Biosciences beats 4D Molecular Therapeutics on 9 of the 16 factors compared between the two stocks.

Get 4D Molecular Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FDMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FDMT vs. The Competition

Export

Metric	4D Molecular Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$498.23M	$2.91B	$6.25B	$12.42B
Dividend Yield	N/A	1.79%	2.69%	5.29%
P/E Ratio	-3.71	17.69	22.29	24.19
Price / Sales	5.85	739.65	581.44	138.36
Price / Cash	N/A	56.38	42.31	57.88
Price / Book	1.08	3.85	9.84	6.72
Net Income	-$140.11M	$75.85M	$3.57B	$337.19M
7 Day Performance	7.68%	-1.68%	-1.17%	0.48%
1 Month Performance	4.84%	22.17%	3.84%	5.06%
1 Year Performance	146.25%	21.83%	27.39%	34.27%

4D Molecular Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FDMT 4D Molecular Therapeutics	2.2435 of 5 stars	$9.53 +2.8%	$29.88 +213.5%	+147.2%	$498.23M	$85.21M	N/A	120
SRPT Sarepta Therapeutics	3.2844 of 5 stars	$16.80 flat	$27.17 +61.7%	-56.9%	$1.77B	$2.20B	N/A	1,372
VCEL Vericel	3.2844 of 5 stars	$34.73 flat	$55.40 +59.5%	-14.9%	$1.77B	$276.26M	82.69	300	Analyst Downgrade
SNDX Syndax Pharmaceuticals	2.5684 of 5 stars	$19.94 flat	$42.55 +113.4%	+67.5%	$1.77B	$172.35M	N/A	110	Analyst Forecast Insider Trade
NTLA Intellia Therapeutics	2.9791 of 5 stars	$12.60 flat	$20.25 +60.7%	+83.4%	$1.76B	$67.67M	N/A	600

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FDMT) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

4D Molecular Therapeutics (FDMT) Competitors

FDMT vs. SRPT, VCEL, SNDX, NTLA, and HRMY

How does 4D Molecular Therapeutics compare to Sarepta Therapeutics?

Summary

How does 4D Molecular Therapeutics compare to Vericel?

Summary

How does 4D Molecular Therapeutics compare to Syndax Pharmaceuticals?

Summary

How does 4D Molecular Therapeutics compare to Intellia Therapeutics?

Summary

How does 4D Molecular Therapeutics compare to Harmony Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FDMT vs. The Competition

4D Molecular Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

4D Molecular Therapeutics (FDMT) Competitors

FDMT vs. SRPT, VCEL, SNDX, NTLA, and HRMY

How does 4D Molecular Therapeutics compare to Sarepta Therapeutics?

Is SRPT or FDMT more profitable?

Do analysts prefer SRPT or FDMT?

Do insiders and institutionals hold more shares of SRPT or FDMT?

Which has more risk and volatility, SRPT or FDMT?

Which has preferable earnings and valuation, SRPT or FDMT?

Does the media favor SRPT or FDMT?

Summary

How does 4D Molecular Therapeutics compare to Vericel?

Do analysts rate VCEL or FDMT?

Does the media refer more to VCEL or FDMT?

Which has more volatility and risk, VCEL or FDMT?

Which has stronger earnings and valuation, VCEL or FDMT?

Is VCEL or FDMT more profitable?

Do insiders & institutionals believe in VCEL or FDMT?

Summary

How does 4D Molecular Therapeutics compare to Syndax Pharmaceuticals?

Which has stronger earnings & valuation, SNDX or FDMT?

Does the media favor SNDX or FDMT?

Do insiders & institutionals hold more shares of SNDX or FDMT?

Is SNDX or FDMT more profitable?

Do analysts rate SNDX or FDMT?

Which has more risk and volatility, SNDX or FDMT?

Summary

How does 4D Molecular Therapeutics compare to Intellia Therapeutics?

Is NTLA or FDMT more profitable?

Which has higher valuation and earnings, NTLA or FDMT?

Does the media favor NTLA or FDMT?

Do insiders and institutionals have more ownership in NTLA or FDMT?

Which has more risk & volatility, NTLA or FDMT?

Do analysts rate NTLA or FDMT?

Summary

How does 4D Molecular Therapeutics compare to Harmony Biosciences?

Which has more risk & volatility, FDMT or HRMY?

Do analysts prefer FDMT or HRMY?

Which has stronger valuation and earnings, FDMT or HRMY?

Is FDMT or HRMY more profitable?

Do insiders & institutionals have more ownership in FDMT or HRMY?

Does the media refer more to FDMT or HRMY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FDMT vs. The Competition

4D Molecular Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools